https://scholars.lib.ntu.edu.tw/handle/123456789/557701
標題: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study | 作者: | Hochmair M.J. Morabito A. Hao D. Yang C.-T. Soo R.A. CHIH-HSIN YANG Gucalp R. Halmos B. M?rten A. Cufer T. |
關鍵字: | afatinib; EGFR; NSCLC; osimertinib | 公開日期: | 2020 | 出版社: | Future Medicine Ltd. | 卷: | 16 | 期: | 34 | 起(迄)頁: | 2799-2808 | 來源出版物: | Future Oncology | 摘要: | Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ?10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov. ? 2020 Maximilian J. Hochmair and other authors. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097958300&doi=10.2217%2ffon-2020-0740&partnerID=40&md5=0a8b0f96808ac2cee92ae3f29932521e https://scholars.lib.ntu.edu.tw/handle/123456789/557701 |
ISSN: | 1479-6694 | DOI: | 10.2217/fon-2020-0740 | SDG/關鍵字: | afatinib; epidermal growth factor receptor; osimertinib; acrylamide derivative; afatinib; aniline derivative; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; aged; Article; Asian; cancer chemotherapy; cancer survival; clinical practice; clinical trial; controlled study; gene mutation; human; major clinical study; non small cell lung cancer; observational study; overall survival; priority journal; survival rate; survival time; adult; genetics; lung tumor; middle aged; mortality; mutation; non small cell lung cancer; Acrylamides; Adult; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutation |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。